Prostate cancer is largely thought of as a men’s disease.

But this framing leaves out half a million U.S. adults with a prostate: transgender women.

A new study published in the journal JAMA found that a lack of established reference ranges for prostate-specific antigen (PSA) values for the trans population may be having deadly consequences.

“As the political climate shifts, and as we become more accepting, progressive and inclusive as a society, we are going to see more people openly identifying as transgender,” said Farnoosh Nik-Ahd, resident physician in the urology department at the University of California, San Francisco School of Medicine and first author on the paper.

Advertise with us

“The reality is, we’re really at the beginning of our understanding of how best to take care of transgender patients, not just with prostate cancer, but in many aspects of their health,” said Nik-Ahd. “So this is a huge area where a lot of research is needed.”

Measuring the levels of prostate-specific antigen, a kind of protein, in the blood can tell doctors whether or not the body is fighting cancer. This blood test has become a key way to test for prostate cancer, as it’s more comprehensive than a traditional rectal exam. A higher PSA value, measured in nanograms per milliliter, is associated with prostate cancer: Alarms go off typically around 4 ng/mL.

Prostate cancer diagnoses among trans women between 2000 and 2022 were more common than previously thought, with 14 out of 100,000 developing the disease, according to 2023 research including Nik-Ahd. And often these diagnoses were caught at later stages, increasing their risk of mortality from the disease.

Why is this happening? Well, the working theory is that estrogen and estrogen-related drugs, like estradiol — which many trans women take as part of their transition — drive PSA values down. This means PSA values look within the “normal” reference range, even if there’s cancer present.

But it’s not well-understood how estrogen specifically changes prostate cancer outcomes, said Nik-Ahd. There’s evidence that it has a protective effect on prostate cancer, while other studies show it exacerbates it. This is one reason more research is warranted.

Advertise with us

Nik-Ahd is calling for PSA values in trans women to be interpreted with caution due to these results. Her team is also working to establish a separate reference range for this population and continue their research on the health of this population.

The study found that, for trans women whose health data was analyzed, the median PSA value was 0.02 ng/mL — for context, the median range for cisgender men is 1 ng/mL. The highest PSA value in the cohort of trans women was 2.21. Additionally, PSA values were undetectable in 36% of patients studied.

“There is not a lot of emphasis placed on trans research,” said Charlie Borowicz, transgender health project manager at Allegheny Health Network’s Center for Inclusion Health, and who is trans nonbinary. “That means we’re not able to come up with specific risk profiles for trans people for their medical transition.”

Once cancer spreads beyond the prostate, the five-year survival rate drops from 99% to 34%, per the American Cancer Society, stressing the importance of catching prostate cancer at its earliest stages.

In the past few years, prostate cancer deaths have plateaued after declining for decades. Some experts believe this is due to cases being caught at these later stages.

Advertise with us

“With some of the work that we have planned ahead, we’ll be able to provide more specific reference ranges for people to use in the future, and also just help put it on people’s radar that this is a hugely marginalized population,” said Nik-Ahd. “[We want to] learn more about their health outcomes and how to best take care of them.”

The current research helps to establish a “new normal” for trans patient PSA values. Future work might include a control group for comparison so researchers can understand better where the danger zone lies.

“If the [previous] screening tool is not accurate for this population, that’s where the problem is, and that’s where we need more research,” Borowicz said.

Borowicz hopes to see more robust and longer-term research on the health of trans people, who often already struggle to access health care or otherwise have negative experiences with doctors who aren’t used to treating trans patients.

They also called for more provider education about trans patients.

“Prostate cancer specialists need to think about all populations that may have a prostate,” said Borowicz. “Those populations may look different. Everybody should be prepared to treat trans people.”